Gerresheimer's Creditor Truce and Asset Sale Plan Chart a Path Forward

German pharma packager Gerresheimer secures covenant suspension until 2026, sells US unit Centor, and rejects Silgan takeover to pursue independent restructuring.

The German pharmaceutical packaging specialist Gerresheimer has secured crucial breathing room from its lenders, buying time to finalize long-delayed financial statements and execute a vital asset sale. In a week of significant developments, the company also confirmed it had rejected a takeover approach from US rival Silgan Holdings, choosing to focus on its internal restructuring first.

Creditors holding 96% of the company's Schuldschein debt agreed to extend key deadlines until the end of September 2026. This suspension of leverage-based covenants provides a lifeline, allowing management to concentrate on completing the audited financial statements for 2025, now expected in June, and the subsequent first-quarter report. The delay stems from an internal accounting investigation, with a second audit firm examining revenue recognition and inventory valuation for 2024 and 2025.

Concurrently, the process to sell the profitable US subsidiary Centor Inc. is gaining momentum. Morgan Stanley, mandated with the sale, has attracted interest from more than ten potential buyers for the unit, which carries a book value of 292 million euros. Gerresheimer aims to complete the divestment before the end of the year. The proceeds are earmarked to alleviate the company's capital structure, burdened by net financial debt of approximately 1.2 billion euros.

These moves follow the collapse of takeover talks with Silgan. According to Reuters, the US competitor had been working on a non-binding offer of 41 euros per share in March—more than double the share price at the time. While the stock initially dipped on the news, it recovered to close up 1.7% on the day, later rising to 21.40 euros. This reflects a market cautiously balancing the lost premium against the potential of a successful standalone turnaround.

Analyst reactions are measured. Bernstein's Delphine Le Louet described the creditor agreement as a "small relief," noting the management's decisions offer transparency that could prevent insolvency. However, she warned that the costs of renegotiating the covenants could be 10 to 20 million euros above the original 100 million euro estimate. Jefferies' James Vane-Tempest pointed to a solid order book, confirming the 2026 business development is proceeding according to plan.

The company's operational targets for 2026 remain intact, with management guiding for revenue of 2.3 to 2.4 billion euros and an adjusted EBITDA margin of 18% to 19%. The next major milestone will be the half-year report on July 14, 2026, which should provide clarity on the progress of the Centor sale.

Despite the recent rally, which places the share about 37% above its February low, a significant gap remains to its 52-week high of 64.40 euros. The path ahead is clearly defined: finalize the accounts, sell Centor, and strengthen the balance sheet. Only then, as the company has communicated, will broader strategic options truly be back on the table.